Companies
Biocon
Biosimilars + local build — EMA-approved India mAbs site.
- Country
- India
Commercial
Biosimilars / Emerging Markets
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Rs 4,150 crore (~USD 460 million) equity fundraise via Qualified Institutions Placement (QIP) concluded in January 2026 | bioconbiologics.com |
| Production site | 350,000 sq. ft. mAbs Drug Substance (B3) facility at Biocon Park, Bengaluru, India | biocon.com · bioprocessintl.com |
| Capacity | 42,000 L capacity at the Bengaluru mAbs facility | bioprocessintl.com |
| Regulatory approval | EMA approved for manufacture of biosimilar Bevacizumab and Trastuzumab at Bengaluru mAbs facility | biocon.com · bioprocessintl.com · prnewswire.com |
| Certification | Renewed GMP Certificates of Compliance for Bengaluru and Malaysia sites issued by HPRA on behalf of EMA (as of June 2024) | biocon.com · bioprocessintl.com · prnewswire.com |
| Headcount | 18,200+ total employees (Biocon Group, as of FY2025) | biocon.com |
| Revenue | Biocon Limited revenue: USD 1.9 billion; Biocon Biologics revenue: USD 1.1 billion (FY2025) | biocon.com |
Independent sources: bioprocessintl.com · prnewswire.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
| Local manufacturing for market access | market-access-commercial | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.